A few molecularly guided systemic treatment options have shown clinical benefit, including anti-EGFR agents in KRAS/NRAS (RAS) wild-type cancers with a left-sided primary tumor location [16], immune checkpoint inhibitors against MSI cancers [17, 18], and targeted combination therapies against BRAFV600E mutated cancers [19]. This evidence concerns the gene NRAS and cancer.